Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis

被引:3
|
作者
Veettil, Sajesh K. [1 ,2 ]
Kew, Siang Tong [3 ]
Lim, Kean Ghee [4 ]
Phisalprapa, Pochamana [5 ]
Kumar, Suresh [2 ]
Lee, Yeong Yeh [6 ,7 ]
Chaiyakunapruk, Nathorn [1 ,8 ]
机构
[1] Univ Utah, Dept Pharmacotherapy, Coll Pharm, 30 2000 E, Salt Lake City, UT 84112 USA
[2] Int Med Univ, Sch Pharm, Dept Pharm Practice, Kuala Lumpur 57000, Malaysia
[3] Int Med Univ, Dept Internal Med, Sch Med, Kuala Lumpur 57000, Malaysia
[4] Int Med Univ, Dept Surg, Jalan Rasah, Seremban 70300, Negeri Sembilan, Malaysia
[5] Mahidol Univ, Fac Med, Dept Med, Div Ambulatory Med,Siriraj Hosp, Bangkok 10700, Thailand
[6] Univ Sains Malaysia, Sch Med Sci, Kota Baharu, Kelantan, Malaysia
[7] Natl Univ Malaysia, Fac Med, Gut Res Grp, Kuala Lumpur, Malaysia
[8] Monash Univ Malaysia, Sch Pharm, Subang Jaya 47500, Selangor, Malaysia
关键词
Colorectal cancer; Colorectal adenomas; Chemoprevention; Aspirin; Surveillance colonoscopy; Network meta-analysis; Cost-effectiveness analysis; TRIAL SEQUENTIAL-ANALYSIS; TASK-FORCE; CELECOXIB; CALCIUM; RISK; CHEMOPREVENTION; INTERVENTIONS; RECURRENCE; MORTALITY; REVIEWS;
D O I
10.1186/s12876-021-01715-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundIndividuals with advanced colorectal adenomas (ACAs) are at high risk for colorectal cancer (CRC), and it is unclear which chemopreventive agent (CPA) is safe and cost-effective for secondary prevention. We aimed to determine, firstly, the most suitable CPA using network meta-analysis (NMA) and secondly, cost-effectiveness of CPA with or without surveillance colonoscopy (SC).MethodsSystematic review and NMA of randomised controlled trials were performed, and the most suitable CPA was chosen based on efficacy and the most favourable risk-benefit profile. The economic benefits of CPA alone, 3 yearly SC alone, and a combination of CPA and SC were determined using the cost-effectiveness analysis (CEA) in the Malaysian health-care perspective. Outcomes were reported as incremental cost-effectiveness ratios (ICERs) in 2018 US Dollars ($) per quality-adjusted life-year (QALY), and life-years (LYs) gained.ResultsAccording to NMA, the risk-benefit profile favours the use of aspirin at very-low-dose (ASAVLD,<= 100 mg/day) for secondary prevention in individuals with previous ACAs. Celecoxib is the most effective CPA but the cardiovascular adverse events are of concern. According to CEA, the combination strategy (ASAVLD with 3-yearly SC) was cost-saving and dominates its competitors as the best buy option. The probability of being cost-effective for ASAVLD alone, 3-yearly SC alone, and combination strategy were 22%, 26%, and 53%, respectively. Extending the SC interval to five years in combination strategy was more cost-effective when compared to 3-yearly SC alone (ICER of $484/LY gain and $1875/QALY). However, extending to ten years in combination strategy was not cost-effective.ConclusionASAVLD combined with 3-yearly SC in individuals with ACAs may be a cost-effective strategy for CRC prevention. An extension of SC intervals to five years can be considered in resource-limited countries.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis
    Sajesh K. Veettil
    Siang Tong Kew
    Kean Ghee Lim
    Pochamana Phisalprapa
    Suresh Kumar
    Yeong Yeh Lee
    Nathorn Chaiyakunapruk
    [J]. BMC Gastroenterology, 21
  • [2] Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis
    Hassan, Cesare
    Rex, Douglas K.
    Cooper, Gregory S.
    Zullo, Angelo
    Launois, Robert
    Benamouzig, Robert
    [J]. GUT, 2012, 61 (08) : 1172 - 1179
  • [3] COST-EFFECTIVENESS ANALYSIS OF CHEMOPREVENTION FOR COLORECTAL CANCER BY LOW DOSE ASPIRIN IN SOUTH KOREA
    Lee, J. Y.
    Lee, E. K.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A447 - A447
  • [4] Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer - A cost-effectiveness analysis
    Ladabaum, U
    Chopra, CL
    Huang, G
    Scheiman, JM
    Chernew, ME
    Fendrick, AM
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 135 (09) : 769 - 781
  • [5] Low-dose aspirin for prevention of preeclampsia and its complications: a cost-effectiveness analysis
    Vogel, Sinae
    Rajaii, Roxanne
    Ottaviano, Geri
    Kim, Lena
    Yeaton-Massey, Amanda
    Caughey, Aaron
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 201 (06) : S218 - S218
  • [6] Risk of Advanced Adenoma, Colorectal Cancer, and Colorectal Cancer Mortality in Individuals With Low Risk Adenomas on Baseline Colonoscopy: A Systematic Review and Meta-Analysis
    Dube, Catherine
    Yakubu, Mafo
    McCurdy, Bronwen
    Lischka, Andrea
    Tinmouth, Jill
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S61 - S61
  • [7] Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy A Cost-Effectiveness Analysis
    Greuter, Marjolein J. E.
    de Klerk, Clasine M.
    Meijer, Gerrit A.
    Dekker, Evelien
    Coupe, Veerle M. H.
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (08) : 544 - +
  • [8] Aspirin versus Screening for Colorectal Cancer Prevention: Comparative Effectiveness Network Meta-Analysis
    Emilsson, Louise
    Holme, Oeyvind
    Bretthauer, Michael
    Cook, Nancy R.
    Buring, Julie E.
    Loberg, Magnus
    Adami, Hans-Olov
    Sesso, Howard D.
    Gaziano, Michael
    Kalager, Mette
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S452 - S452
  • [9] Low-dose versus medium-dose aspirin for preeclampsia prevention in pregnancy: a cost-effectiveness analysis
    Saito, Tanya
    Speranza, Rosa
    Vinson, Abbie
    Hersh, Alyssa R.
    Caughey, Aaron B.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 222 (01) : S144 - S145
  • [10] Gastroprotection in Low-Dose Aspirin Users for Primary and Secondary Prevention of ACS: Results of a Cost-Effectiveness Analysis Including Compliance
    de Groot, N. L.
    van Haalen, H. G. M.
    Spiegel, B. M. R.
    Laine, L.
    Lanas, A.
    Focks, J. Jaspers
    Siersema, P. D.
    van Oijen, M. G. H.
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2013, 27 (04) : 341 - 357